Teva - Aggressive Cuts Provide Relief

16/12/2017 18:04

In early October I looked at the prospects for Teva (TEVA) in an article titled, ¨Copaxone competition comes at the worst time¨. Shares were under pressure following the launch of a competing drug by Mylan (MYL) in a move which could cut operating earnings by $1.3 billion a year.

The timing of this news has been very unfortunate as Teva has already been under a lot of pressure after the acquisition of the generics business from Allergan backfired, and put a lot of (financial) pressure on the company. The company continues

Read more ...

More News

Adobe: Strong Finish To 2017

16/12/2017 15:41

There's a reason Adobe (NASDAQ: ADBE ) is consistently trending toward all-time highs: the ne...

An 11% Yield, With No K-1, On Qualified Dividends, From A Solid LP

16/12/2017 16:02

Trying to find high-yield income without the hassle of a K-1 at tax time? Maybe you should tak...

It's A Mad, Mad, Mad, Mad World

16/12/2017 16:35

I'm reasonably sure this has been mentioned by someone writing on this platform, and if it has...

Download our official mobile apps today. is an educational platform. We DO NOT deal with securities and receive any financial benefits from Financial Products & Service Providers.
All Rights Reserved © 2016 - 2018